ENT Liu Knowledge Base Head & neck tumours · physician reviewed
Salivary Gland Tumours · Prognosis & follow-up

What is the prognosis for salivary gland tumours?

Reviewed: 8 November 2026 By: Xiangpeng Liu, MD Topic: Salivary Gland Tumours Answer length: short, citable
Quick answer

Benign pleomorphic adenoma has excellent outcomes after complete excision. Low-grade malignant tumours often have five-year survival above 80%, while high-grade tumours, salivary duct carcinoma and node-positive disease do considerably worse. Adenoid cystic carcinoma is notable for late local recurrence and distant metastasis, so follow-up extends beyond five years; facial nerve function and chronic recurrence are the main quality-of-life issues.

In detail

Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment.

Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance.

What this means in practice: this answer is part of the “Prognosis & follow-up” section of the Salivary Gland Tumours topic. If you are comparing treatment options, also read how to compare a second opinion and which records to send.

Other common questions about salivary gland tumours

See all 14 questions in this topic →

Sources for this answer

  1. NCCN Guidelines for Patients: Head and Neck Cancers National Comprehensive Cancer Network · 2025
  2. Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 CA: A Cancer Journal for Clinicians · 2026 · Subsite-level estimates for 185 countries; the basis of the regional atlas on this site.
  3. Global Cancer Observatory (GLOBOCAN 2022) International Agency for Research on Cancer / WHO · 2022 · Source of worldwide and country-level incidence and mortality estimates.
  4. Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) European Medicines Agency · 2025 · Reports the combined 947,211 head and neck cancer cases in 2022 and regional ASRs.
  5. NCCN Guidelines for Patients: Head and Neck Cancers National Comprehensive Cancer Network · 2025

Written and medically reviewed by Xiangpeng Liu, MD

Associate Chief Physician, ENT & Head/Neck Surgery · Chenzhou First People’s Hospital, Chenzhou, Hunan, China

Editorial policy & reviewer credentials · All sources

← Previous questionWhat are the treatment options for salivary gland tumours? Next question →Can salivary gland tumours be prevented?

Need an opinion on your own case?

International patients can request a preliminary review based on pathology and imaging before travelling to China.

How the pathway works Send an enquiry

Medical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.